FDA approves Flexion's Zilretta for OA knee pain

FDA approved Zilretta sustained-release triamcinolone acetonide (FX006) from Flexion Therapeutics Inc. (NASDAQ:FLXN) to treat osteoarthritis (OA) knee pain.

Flexion plans to launch the product this month at a price of $570 per dose. The company said Zilretta is designed to deliver pain relief over 12 weeks in patients with moderate to severe OA knee pain...